Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells $65,248.38 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) major shareholder James C. Czirr sold 21,323 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $3.06, for a total transaction of $65,248.38. Following the transaction, the insider now directly owns 5,925,884 shares in the company, valued at approximately $18,133,205.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Galectin Therapeutics Stock Performance

Shares of GALT stock opened at $3.45 on Friday. The stock’s 50 day simple moving average is $2.61 and its 200 day simple moving average is $2.12. Galectin Therapeutics Inc. has a twelve month low of $1.28 and a twelve month high of $4.27. The company has a market capitalization of $213.56 million, a price-to-earnings ratio of -4.66 and a beta of 0.84.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Friday, March 29th. The company reported ($0.16) EPS for the quarter. On average, analysts forecast that Galectin Therapeutics Inc. will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Retirement Guys Formula LLC increased its stake in shares of Galectin Therapeutics by 87.0% in the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company’s stock worth $36,000 after purchasing an additional 10,000 shares during the period. Beacon Capital Management LLC boosted its stake in Galectin Therapeutics by 89.6% during the 4th quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock valued at $40,000 after purchasing an additional 11,300 shares during the period. AE Wealth Management LLC grew its holdings in Galectin Therapeutics by 72.7% in the 3rd quarter. AE Wealth Management LLC now owns 26,841 shares of the company’s stock valued at $52,000 after buying an additional 11,300 shares during the last quarter. Solutions 4 Wealth Ltd bought a new position in Galectin Therapeutics in the 4th quarter worth approximately $60,000. Finally, D.A. Davidson & CO. lifted its holdings in shares of Galectin Therapeutics by 15.2% during the third quarter. D.A. Davidson & CO. now owns 37,825 shares of the company’s stock worth $73,000 after buying an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 11.68% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on GALT shares. StockNews.com upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Tuesday, April 9th.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.